Publicaciones en colaboración con investigadores/as de Université Denis Diderot (91)

2019

  1. Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity

    Cell Metabolism, Vol. 30, Núm. 4, pp. 754-767.e9

  2. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial

    The Lancet HIV, Vol. 6, Núm. 10, pp. e655-e666

  3. Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years

    Scientific Reports, Vol. 9, Núm. 1

  4. European consensus meeting/statement on Bronchial Thermoplasty Who? Where? How?

    Respiratory Medicine

  5. Newborn screening for sickle cell disease in Europe

    International Journal of Neonatal Screening, Vol. 5, Núm. 1

  6. Phenotype, treatment practice and outcome in the cobalamin-dependent remethylation disorders and MTHFR deficiency: Data from the E-HOD registry

    Journal of Inherited Metabolic Disease, Vol. 42, Núm. 2, pp. 333-352

  7. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: The 302 study

    Blood, Vol. 133, Núm. 6, pp. 540-549

  8. Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?

    Diabetes and Metabolic Syndrome: Clinical Research and Reviews, Vol. 13, Núm. 4, pp. 2723-2725

  9. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: Conceptual framework and therapeutic potential

    Cardiovascular Diabetology, Vol. 18, Núm. 1

  10. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

    Antiviral Research, Vol. 170

2018

  1. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

    The Lancet HIV, Vol. 5, Núm. 1, pp. e23-e34

  2. Global overview of the transnational alliance for regenerative therapies in cardiovascular syndromes (TACTICS) Recommendations: A comprehensive series of challenges and priorities of cardiovascular regenerative medicine

    Circulation Research, Vol. 122, Núm. 2, pp. 199-201

  3. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204

  4. Newborn screening for sickle cell disease in Europe: recommendations from a Pan-European Consensus Conference

    British Journal of Haematology, Vol. 183, Núm. 4, pp. 648-660

  5. Prosthetic Valve Candida spp. Endocarditis: New Insights into Long-term Prognosis-The ESCAPE Study

    Clinical Infectious Diseases, Vol. 66, Núm. 6, pp. 825-832

  6. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness

    New England Journal of Medicine, Vol. 379, Núm. 12, pp. 1118-1127

  7. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

    The Lancet, Vol. 392, Núm. 10151, pp. 940-949

2017

  1. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms

    Antimicrobial Agents and Chemotherapy, Vol. 61, Núm. 2

  2. Erratum: Antimicrobials: A global alliance for optimizing their rational use in intra-abdominal infections (AGORA). [World J Emerg Surg. 11, (2016) (33)] DOI: 10.1186/s13017-016-0089-y

    World Journal of Emergency Surgery

  3. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017

    European Journal of Cancer, Vol. 77, pp. 57-74